<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03414021</url>
  </required_header>
  <id_info>
    <org_study_id>OBS-0030</org_study_id>
    <nct_id>NCT03414021</nct_id>
  </id_info>
  <brief_title>Interest of the SPECT-CT Scan SUVspect in the New Generation of Gamma-cameras With Semiconductor</brief_title>
  <acronym>GAMMA-CAM</acronym>
  <official_title>Quantification in Nuclear Medicine: Interest of the in SPECT-CT Scan SUVspect in Thea New Generation of Gamma-cameras With Semiconductor. Data Collection for the Constitution of an Observatory of Scintigraphies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lille Catholic University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lille Catholic University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since 2017, a revolution began in the departments of nuclear medicine, with the routine use
      of gamma-cameras with semiconductor. These gamma-cameras (which obtained the CE-marking in
      2016), offer a technological breakthrough by providing an additional information. They allow
      &quot;to quantify&quot; for the 1st time in clinical routine conditions, the quantity of radioactivity,
      by means of a &quot;SUVspect&quot;, in a volume of interest, while respecting the recommendations of
      best practice of the learned societies of French nuclear medicine (SFMN), European (EANM) and
      American (SNM), without injection of tracer nor acquisition or additional irradiation. The
      SUVspect is therefore an indicator of the quantity of tracer in a given volume of
      acquisition.

      Until now, the interpretation criteria of scintigraphies are based on the homogeneity of
      distribution of a tracer in the explored organ (for single organs such as the heart or the
      thyroid, for example) or in the asymmetry of distribution of the tracer (for the double
      organs, such as the kidney or the joints).

      This new gamma-camera allows to study the distribution of the radio-tracers in &quot;list&quot; mode,
      allowing to retrospectively reconstruct the images in various ways (for example, by modifying
      the size of the matrix of acquisition, the energy windows, the time of acquisition).
      Therefore, we can simulate and propose modifications in current procedures.

      Every patient referred to our department of nuclear medicine to undergo a scintigraphy with a
      tracer of nuclear medicine (with a marketing authorization) can, while benefiting from an
      examination by this gamma-camera, to be the object of this study, and to profit from this
      additional information.

      So, without changing the diagnosis or the usual care, we wish to take advantage of this
      additional information to improve the criteria of interpretation of our examinations.

      This possibility being new, there is no available bibliography (our department is the 5th
      department of nuclear medicine in Europe to equip itself with this large field-of-view
      gamma-camera CZT, the DNM 670, made by General Electric), while 2961 articles speak about the
      SUVmax (in PET) in Pubmed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 31, 2018</start_date>
  <completion_date type="Anticipated">January 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>SUVspect</measure>
    <time_frame>5 years</time_frame>
    <description>Pathological threshold (SUVspect) for every type of scintigraphy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Matrix size</measure>
    <time_frame>5 years</time_frame>
    <description>Optimize the reconstruction parameters of the images</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of image acquisition</measure>
    <time_frame>5 years</time_frame>
    <description>Optimize the reconstruction parameters of the images</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Thyroid Diseases</condition>
  <condition>Heart Diseases</condition>
  <condition>Bone Diseases</condition>
  <condition>Brain Diseases</condition>
  <condition>Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>Thyroid Diseases</arm_group_label>
    <description>SPECT-CT Scan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heart Diseases</arm_group_label>
    <description>SPECT-CT Scan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bone Diseases</arm_group_label>
    <description>SPECT-CT Scan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brain Diseases</arm_group_label>
    <description>SPECT-CT Scan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kidney Diseases</arm_group_label>
    <description>SPECT-CT Scan</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>SPECT-CT Scan</intervention_name>
    <description>Injection of a Tracer and SPECT-CT Scan</description>
    <arm_group_label>Thyroid Diseases</arm_group_label>
    <arm_group_label>Heart Diseases</arm_group_label>
    <arm_group_label>Bone Diseases</arm_group_label>
    <arm_group_label>Brain Diseases</arm_group_label>
    <arm_group_label>Kidney Diseases</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Every patient referred to our departments of nuclear medicine for a nuclear médicine
        exploration
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - informed adult patients referred to our department of nuclear medicine for a nuclear
        medicine exploration

        Exclusion Criteria:

          -  Refusal to participate

          -  Patient under guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanguy Blaire, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GIE HUMANITEP, GHICL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alban Baillez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GIE HUMANITEP, GHICL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amélie Lansiaux, MD, PhD</last_name>
    <phone>03 20 22 52 69</phone>
    <phone_ext>+33</phone_ext>
    <email>lansiaux.amelie@ghicl.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Jacques Vitagliano, PhD</last_name>
    <phone>03 20 22 57 51</phone>
    <email>vitagliano.jean-jacques@ghicl.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Humanitep</name>
      <address>
        <city>Lomme</city>
        <state>Hauts De France</state>
        <zip>59462</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanguy Blaire, MD, PhD</last_name>
      <phone>03.20.00.24.14</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Tanguy Blaire, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bailliez Alban, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Privé Le Bois</name>
      <address>
        <city>Lille</city>
        <state>Hauts-de-France</state>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tanguy Blaire, MD, PhD</last_name>
      <phone>03.20.09.92.92</phone>
      <phone_ext>+33</phone_ext>
    </contact>
    <investigator>
      <last_name>Tanguy Blaire, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alban Bailliez, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2018</study_first_submitted>
  <study_first_submitted_qc>January 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2018</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nuclear Medicine</keyword>
  <keyword>SPECT-CT Scan</keyword>
  <keyword>gamma-camera with semiconductor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Bone Diseases</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

